Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Amortizatization of Intangibles: 2015-2024

Historic Amortizatization of Intangibles for Protagonist Therapeutics (PTGX) over the last 10 years, with Dec 2024 value amounting to $8.9 million.

  • Protagonist Therapeutics' Amortizatization of Intangibles fell 40.66% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 15.86%. This contributed to the annual value of $8.9 million for FY2024, which is 94.24% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Amortizatization of Intangibles of $8.9 million as of FY2024, which was up 94.24% from $4.6 million recorded in FY2023.
  • Protagonist Therapeutics' Amortizatization of Intangibles' 5-year high stood at $8.9 million during FY2024, with a 5-year trough of $1.8 million in FY2020.
  • In the last 3 years, Protagonist Therapeutics' Amortizatization of Intangibles had a median value of $4.6 million in 2023 and averaged $5.3 million.
  • In the last 5 years, Protagonist Therapeutics' Amortizatization of Intangibles decreased by 0.95% in 2020 and then spiked by 95.67% in 2023.
  • Yearly analysis of 5 years shows Protagonist Therapeutics' Amortizatization of Intangibles stood at $1.8 million in 2020, then grew by 10.54% to $2.0 million in 2021, then climbed by 19.01% to $2.3 million in 2022, then skyrocketed by 95.67% to $4.6 million in 2023, then surged by 94.24% to $8.9 million in 2024.